T Cell response to Pfizer’s Covid vaccine

[Twin21]

Just thought I’d share a medical journal study on the T cell response to Pfizer’s Covid vaccine. This study doesn’t mention CLL or immune compromised responses but it does suggest there are tests to measure T cell responses to the Covid vaccines. Hopefully we will hear about CLL patient’s T cell responses to the Covid vaccine soon.

An assessment of humoral and T cell responses against a wild type SARS-CoV-2 strain, variants of concern (B.1.1.7, B.1.351, and P.1), and endemic human coronaviruses (hCov) induced after the Pfizer-BioNTech vaccine found that IgG against the receptor-binding domain of the SARS-CoV-2 S protein was readily detectable at day 14, but inhibition of SARS-CoV-2 S-driven host cell entry was weak and particularly low for the B.1.351 variant. After one vaccine dose, frequencies of SARS-CoV-2 specific T cells were low in many vaccine recipients and influenced by immunity against endemic hCoV. The second vaccination significantly boosted T cell frequencies reactive for the wild type SARS-CoV-2 strain, as well as B.1.1.7 and B.1.351 variants:

medrxiv.org/content/10.1101...

[cllady01 Former Volunteer]

Thank you for the post. This full view of the not-yet- peer reviewed article, and quote: Just cutting to the summary. Seems there are many working to get the answers we would like to have. May they succeed to give us any protection we can get.

Our study is limited by the fact that we were unable to assess T cell responses before vaccination. Secondly, the analyzed cellular responses would benefit from further identification of T cell subsets and viral epitopes involved. Third, our study only considers systemic responses and studies of airway compartments or tissue-resident T cells may be important to gain additional insights into protective immunity after vaccination against COVID-19.

In summary, our data demonstrate suboptimal neutralizing antibody activity against SARS-CoV-2 WT and VOC after a single BNT162b2 vaccination, in keeping with a study deposited on a preprint server (26). T cells, which responded equally to spike-derived peptides from SARS-CoV-2 WT, B.1.1.7 and B.1.351 were detectable with a broad inter-individual range and influenced by cross-reactive T cells against hCoV. We propose that non-neutralizing antibody function and/or cellular immunity constitute an important outcome after vaccination and may be part of the early defense against SARS-CoV-2 infection. We conclude that without an immune correlate of protection for SARS-CoV-2 vaccines, protective immunity after vaccination cannot be precisely measured and variations in effective immunization programs cannot be confidently recommended (26, 28).

medrxiv.org/content/10.1101...